Please assess the completion status of the following clinical trial:

Trial Title: Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The study population will consist of eighty subjects who are 18 years or older and have a biopsy-proven lentigo maligna.~* The subjects must have a LM that is in a location amenable to treatment with imiquimod, express a willingness and ability to comply with study requirements, and tolerate an outpatient surgical procedure.~* All participants will sign consent documents prior to enrollment.~* The typical age of patient that develops a LM is beyond the child-bearing range.~Exclusion Criteria:~* In the event that a patient with a LM is pregnant, they will be excluded from the study.~* inability to tolerate the surgical procedure~* invasive melanoma~* previous surgery on the site of interest

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Topical imiquimod group:~treat the LM site two centimeters beyond the perimeter margin with topical imiquimod 5% cream Monday thru Friday of each week for a total of twelve weeks. After three months of topical treatment, a one-month wash out period will be observed to allow for resolution of inflammation that can obscure the pathologist's ability to evaluate the excised tumor/treatment site.
- 2 (Type: EXPERIMENTAL): Topical imiquimod and topical tazarotene 0.1% cream group:~Patients randomized to this group will undergo an identical treatment protocol as the topical imiquimod group with the addition of topical tazarotene 0.1% cream on Saturday and Sunday of each week.

Based on this trial design, predict the completion outcome and termination type (if applicable).